Current Speakers for Life Sciences Patent Network North America Include:
Kristina Bieker-Brady
Kristina Bieker-Brady
McDermott Will & Emery
Partner
Kris represents private and public side biotech, pharmaceutical and medical device companies, with a focus on portfolio development, financings, public offerings, mergers and strategic partnerships. Kris is highly skilled in managing multiple facets of clients’ intellectual property portfolio through the majority of the company’s life cycle. Particularly, she works to build and preserve layered exclusivity profiles that are structured to peak in strength during the critical periods of a product’s branded commercial sales life. Kris also advises clients on other matters relating to patent prosecution, including patentability, non-infringement and invalidity opinions, licensing, joint development agreements and patent enforcement.
Robert Sahr
Robert Sahr
Choate Hall & Stewart
Counsel
Robert Sahr is counsel in Choate’s IP and life sciences group. He develops strategies for life science companies to maximise exclusivity for medicines and diagnostics, in particular biologics. He concentrates his practice on building worldwide patent portfolios appropriately aligned with product life cycle. Having worked in research and discovery for a multinational pharmaceutical company, he knows the process, science, and business of bringing regulated products to market. Sahr received his JD from Indiana University School of Law, his PhD from Indiana University School of Medicine and his BA from the State University of New York at Albany.
Brian Slater
Brian Slater
Kramer Levin
Partner
Brian V. Slater, chair of Kramer Levin’s life sciences practice, is a first-chair trial lawyer with more than 25 years of patent litigation experience. He leads trial teams in high-stakes pharmaceutical and biotechnology patent litigation before the district courts and the Patent Trial and Appeal Board. He has defended multibillion-dollar drug products in Hatch-Waxman litigation, and advises clients on navigating the Biologics Price Competition and Innovation Act. Leveraging his courtroom-tested litigation experience and deep industry knowledge, Slater also counsels emerging and established life sciences companies on protecting, licensing and monetising their IP assets.